首页|IL-33/ST2信号通路及相关药物研究进展

IL-33/ST2信号通路及相关药物研究进展

扫码查看
目的:介绍IL-33/ST2信号通路,总结其与各项疾病的发生发展机制之间的关系以及相关药物的研发进展,为相关疾病的治疗策略提供新的思路.方法:通过汇总分析现有的研究IL-33/ST2信号通路与多种疾病的发病机制关联的文献,对IL-33/ST2信号通路与各项疾病之间的关系以及相关药物的研发进展进行讨论总结.结果 与结论:IL-33作为免疫反应和细胞损伤的警报分子,其信号转导通路在过敏性疾病、慢性炎症性疾病、恶性肿瘤和心血管疾病等多种疾病的发病过程中发挥了十分关键的作用,这些研究成果为多种疾病的治疗策略提供了新的思路.多家国内外公司已经开始研发针对IL-33/ST2的靶向药物,绝大多数为单抗药物,且已经进入不同的临床试验阶段,具有重要的应用前景.
Research Advances in IL-33/ST2 Signaling Pathway and Related Drugs
Objective:To introduce the IL-33/ST2 signaling pathway,its correlation with the occurrence and progression of various diseases,and the development of the corresponding drugs,and to provide ideas for developing new treatment strategies of related diseases.Methods:Through a summary analysis of the available literature on the association between IL-33/ST2 signaling pathway and the pathogenesis of various diseases,the correlation between IL-33/ST2 signaling pathway and diseases and the development of related drugs are discussed and summarized.Results and Conclusion:IL-33 acts as an alarm molecule for immune response and cell damage,and its signaling pathway plays a critical role in the pathogenesis of various diseases such as allergic diseases,chronic inflammation,cancers and cardiovascular diseases.These findings provide new targets and ideas for developing treatment strategies for a variety of diseases.Companies around the world have begun to develop drugs targeting IL-33/ST2 signaling pathway,most of which are monoclonal drugs and have entered different clinical trial stages.These drugs have great application prospect.

IL-33/ST2 signaling pathwaypathogenesisdisease treatmenttargeted drugs

杨卜嘉、于传飞、侯书婷、石慧、王兰

展开 >

烟台大学,烟台 264000

中国食品药品检定研究院,北京 102629

IL-33/ST2信号通路 发病机制 疾病治疗 靶向药物

国家重点研发计划

2021YFF060084

2024

中国药事
中国食品药品检定研究院(中国药品生物制品检定所)

中国药事

CSTPCD
影响因子:0.844
ISSN:1002-7777
年,卷(期):2024.38(1)
  • 63